Author: Jane Edwards|| Date Published: December 8, 2020
Palantir Technologies (NYSE: PLTR) has received a potential three-year, $44.4M contract from the Food and Drug Administration to provide software that could be used to analyze data associated with drug reviews and inspections, Bloomberg reported Monday.
The FDA’s Center for Drug Evaluation and Research and the Oncology Center of Excellence will use Palantir software to facilitate the approval process for potential COVID-19 treatments and other drugs and track the safety of hand sanitizers and other items.
The report said government work now accounts for more than half of Palantir’s total revenue. The company is working on software for a new system – Tiberius – that could help federal health officials track the production, distribution and administration of COVID-19 vaccines.
Palantir went public through a direct listing in September and received a valuation of approximately $21B during its trading debut.
Elsevier highlights growing impact of geopolitical tensions on research Governments face tension between security priorities and open science goals AI…
Deltek’s 2026 GovCon Clarity Report found contractors accelerating operations and AI adoption while struggling to maintain profitability and control. Kevin…
Quiet Professionals, Spathe Systems rebrand as Endurion. New platform combines intelligence, operations and mission technology support. Endurion launches following recent…
John Roese, global chief technology officer and chief artificial intelligence officer at Dell Technologies, said government agencies seeking to advance…
Stockholders of semiconductor foundry SkyWater Technology have approved the company’s merger with quantum computing company IonQ. Quantum computing and post-quantum…
